Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGorafenib + nIvolumab and short-course radiotherapy in intermediate-risk stage II-III rectal cancer (Phase II)
2024-516554-22-00Phase 2Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab and regorafenib in rectal cancer, sponsored by Institut Jules Bordet. Primary endpoint: Complete response rate (pCR + cCR) in pMMR/MSS tumours. Planned start Aug 2024; status: authorised.
02
Drugs
nivolumabregorafenib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-516554-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516554-22-00.